Enterprise Value
223.1M
Cash
27.12M
Avg Qtr Burn
-9.143M
Short % of Float
7.83%
Insider Ownership
2.73%
Institutional Own.
36.00%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Liver Dominant metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Approved Quarterly sales | |
CHEMOSAT® Details Uveal melanoma | Phase 2 Data readout | |
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Intrahepatic cholangiocarcinoma | Failed Discontinued |